Nordea downgraded Novo Nordisk (NVO) to Hold from Buy. The firm sees a lack of near-term catalysts following yesterday’s obesity study results.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO: